Ayse UGUR, Sukru Gokhan ELCİ, Doğangün YÜKSEL

Validation of HPLC method for the determination of chemical and radiochemical purity of a Ga-68-labelled EuK-Sub-kf-(3-iodo-y-) DOTAGA

The prostate-specific membrane antigen (PSMA) represents an ideal biomarker for molecular imaging. Various PSMA-targeted radioligands are available for prostate cancer imaging. In this study, labeling of PSMA I&T with Ga-68, as well as validation of the radiochemical purity of the synthesis product by reverse phase radio high-performance liquid chromatography (HPLC) method are intended. Since the standard procedure for the quality control (QC) was not available, definition of chemical and radiochemical purity of Ga-68-PSMA I&T was carried out according to the Q2 (R1) ICH guideline. The standard QC tests were analyzed with Scintomics 8100 radio-HPLC system equipped with a radioactivity detector. The method was evaluated in terms of linearity, precision and accuracy, LOQ, robustness parameters, and specificity. To assess the radiochemical and chemical purity of Ga-68-PSMA I&T, the developed method was validated to apply safely to patients. An excellent linearity was found between 1 mu g/mL and 30 mu g/mL, with a limit of detection and limit of quantitation of 0.286 mu g/mL and 0.866 mu g/mL, respectively for Ga-68-PSMA I&T. The recovery was 96.8 +/- 3.8%. The quality control of the final product was performed many times with validated radio-HPLC method and was found to comply with ICH requirements, thus demonstrating the accuracy and robustness of the method for routine clinical practice.

Keywords:

Imaging agents, radiolabeling radiochemical purity, radio-HPLC, quality control,

PDF

___

Agostini ML, 2018, MBIO, V9, DOI 10.1128/mBio.00221-18
Brown AJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104541
Chan K. S., 2003, Hong Kong Medical Journal, V9, P399
Chen F, 2004, J CLIN VIROL, V31, P69, DOI 10.1016/j.jcv.2004.03.003
Dahms SO, 2016, P NATL ACAD SCI USA, V113, P11196, DOI 10.1073/pnas.1613630113
Dhama K, 2020, HUM VACC IMMUNOTHER, V16, P1232, DOI 10.1080/21645515.2020.1735227
Dong LY, 2020, DRUG DISCOV THER, V14, P58, DOI 10.5582/ddt.2020.01012
Fung TS, 2019, ANNU REV MICROBIOL, V73, P529, DOI 10.1146/annurev-micro-020518-115759
Gao JJ, 2020, BIOSCI TRENDS, V14, P72, DOI 10.5582/bst.2020.01047
Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y
Ko WC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105933
Liu K, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-019-0132-8
Liu X, 2020, J GENET GENOMICS, V47, P119, DOI 10.1016/j.jgg.2020.02.001
Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
Sahin K, 2020, TURK J CHEM, V44, P574, DOI 10.3906/kim-1911-57
Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]
Wang Manli, 2020, Cell Res, V30, P269, DOI 10.1038/s41422-020-0282-0
Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045
Wu CR, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101642
Yao XT, 2020, CLIN INFECT DIS, V71, P732, DOI 10.1093/cid/ciaa237
Zhang LL, 2020, SCIENCE, V368, P409, DOI 10.1126/science.abb3405